Moderna has agreed to pay Genevant Sciences and Arbutus Biopharma up to $2.25 billion to settle a patent dispute related to the lipid nanoparticle (LNP) technology essential for its COVID-19 vaccine, Spikevax. The settlement includes an upfront payment of $950 million in July 2026, with an additional $1.3 billion contingent on a separate legal appeal. This agreement resolves all U.S. and international legal actions concerning the unauthorized use of the LNP delivery technology.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute
Moderna has agreed to pay Genevant Sciences and Arbutus Biopharma up to $2.25 billion to settle a patent dispute related to the lipid nanoparticle (LNP) technology essential for its COVID-19 vaccine, Spikevax. The settlement includes an upfront payment of $950 million in July 2026, with an additional $1.3 billion contingent on a separate legal appeal. This agreement resolves all U.S. and international legal actions concerning the unauthorized use of the LNP delivery technology.